Asia Fresh News

Asia Fresh Stories

Archive for January 9th, 2012

OrbusNeich’s Genous(TM) Stent Achieves Good, Comparable Clinical Outcomes in Patients Discontinuing Dual Antiplatelet Therapy at 30 Days and at Six Months

leave a comment »

Twelve-Month Follow-Up Data from a Post-Hoc Analysis of the e-HEALING Registry Published in Catheterization and Cardiovascular Interventions

HONG KONG, Jan. 9, 2012 /PRNewswire-Asia/ — OrbusNeich today announced that 12-month follow-up data from a post-hoc analysis of the e-HEALING registry demonstrates that the company’s Genous Stent achieves good, comparable clinical and safety outcomes in patients discontinuing dual antiplatelet therapy (DAPT) at 30 days and at six months. According to the study, clinical outcomes in patients treated with Genous were not associated with the duration of DAPT. The study has been published online in Catheterization and Cardiovascular Interventions( ).

For the analysis, patients were analyzed according to continuation or discontinuation of DAPT at 30-day and 6-month landmarks, with each landmark constituting a new baseline and the outcomes were assessed up to 12 months after stent placement. Target vessel failure (TVF), the study’s main outcome, was 6.5 percent in patients continuing DAPT at 30 days versus 6.3 percent in patients who stopped at 30 days and 2.4 percent in patients continuing DAPT at 6 months versus 2.9 percent in patients who stopped at 6 months. Notably, no significant differences in stent thrombosis (ST) were observed in patients continuing DAPT compared to those who stopped at 30 days or at six months.

“Studies have shown that early discontinuation of DAPT after the placement of a drug eluting stent is associated with higher rates of stent thrombosis,” said Peter Damman, M.D., of the Academic Medical Center in Amsterdam and first author of the publication. “Unfortunately, for patients who are expected to be non-compliant with their course of DAPT or for those who are at a high risk for bleeding, long-term DAPT is not desirable. These results reaffirm the safety and efficacy of the Genous Stent when accompanied by only one month of DAPT and support the use of Genous as an alternative to drug eluting stents in cases where DAPT may need to be stopped early after stenting.”

The study evaluated patient outcomes from e-HEALING, a multi-center, worldwide prospective clinical registry conducted in 31 countries outside of the United States that included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention (PCI) and Genous Stent implantation. For the analysis, TVF was defined as target vessel-related cardiac death or myocardial infarction and target vessel revascularization.

About Genous Technology

Genous is OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule(TM), R stent, Scoreflex(TM), Sapphire(TM), Sapphire II and Sapphire NC. Development stage products include the Combo(TM) Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, mainland China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit

Follow OrbusNeich on Twitter at, and learn more about the company and the Genous technology on OrbusNeich’s YouTube Channel:


Written by asiafreshnews

January 9, 2012 at 11:02 am

Posted in Uncategorized

Capital Engineering Corporation Joins AECOM

leave a comment »

Renowned environmental and engineering consultancy expands AECOM’s global footprint

HONG KONG, Jan. 6, 2012 /PRNewswire-Asia/ — AECOM Technology Corporation (NYSE: ACM), a leading provider of professional technical and management support services for government and commercial clients around the world, announced today that it has acquired Capital Engineering Corporation (CEC), an environmental and engineering consultancy firm based in Taiwan.

With 160 employees based in Taipei and Kaohsiung, CEC specializes in environmental, water, hydraulic and land development engineering consulting services for clients in Taiwan’s public and private sectors.

The company, which was founded in 1988, provides a wide array of services, including those related to water treatment, river management, industrial park development, environmental surveys and environmental impact assessments.

“CEC’s 24-year track record of providing specialized environmental and engineering services in Taiwan expands our footprint in Asia, which reflects our commitment to growth in new and emerging markets,” said AECOM Chairman and Chief Executive Officer John M. Dionisio. “CEC will serve as a natural fit within AECOM’s global environment and water practices. We are pleased to welcome CEC into the AECOM family and look forward to strengthening our integrated offering to the clients of both firms.”

“Joining AECOM allows us to offer new services within Taiwan and across Asia to meet our growing client demands,” said CEC President Davy Huang. “Additionally, as we grow in Asia, we will be able to provide more professional and career development opportunities for our staff.”


AECOM is a global provider of professional technical and management support services to a broad range of markets, including transportation, facilities, environmental, energy, water and government. With approximately 45,000 employees around the world, AECOM is a leader in all of the key markets that it serves. AECOM provides a blend of global reach, local knowledge, innovation and technical excellence in delivering solutions that create, enhance and sustain the world’s built, natural and social environments. A Fortune 500 company, AECOM serves clients in more than 130 countries and had revenue of US$8.0 billion during its fiscal year 2011. More information on AECOM and its services can be found at .

Forward-Looking Statements: All statements in this press release other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including any projections of earnings, statements of plans for future operations or expected revenue. Actual results could differ materially from those projected or assumed in any of our forward-looking statements. Important factors that could cause actual results to differ materially from our forward-looking statements are set forth in our annual report on Form 10-K for the fiscal year ended Sept. 30, 2011, and our other reports filed with the U.S. Securities and Exchange Commission. AECOM does not intend, and undertakes no obligation, to update any forward-looking statement.

Media Contact

Tony Au
Assistant Manager, Marketing & Communications

Written by asiafreshnews

January 9, 2012 at 10:56 am